The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Unanswered questions in neoadjuvant immunotherapy for lung cancer
David Paul Carbone, MD, PhD, Ohio State University Comprehensive Cancer Center, Columbus, OH, speaks on the current direction of research for neoadjuvant targeted or immunotherapy for lung cancers. There is a great need to define biomarkers that could identify patients that are likely to benefit from adjuvant therapies. Dr Carbone then suggests more research needs to be carried out to determine the ideal timing and duration of these therapies to maximize benefits for patients. This interview was recorded at the American Association for Cancer Research (AACR) Annual Meeting 2022, New Orleans, LA.
